SLI
2.164,99
PKT
+14,01
PKT
+0,65
%
Werbung
Analysen zu SLI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 12.02.25 | Novartis Buy | Deutsche Bank AG | |
| 12.02.25 | ams-OSRAM Buy | Jefferies & Company Inc. | |
| 12.02.25 | ams-OSRAM Buy | UBS AG | |
| 11.02.25 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 11.02.25 | ABB (Asea Brown Boveri) Underperform | Bernstein Research | |
| 11.02.25 | ams-OSRAM Neutral | JP Morgan Chase & Co. | |
| 11.02.25 | UBS Buy | Deutsche Bank AG | |
| 11.02.25 | ams-OSRAM Buy | UBS AG | |
| 11.02.25 | ams-OSRAM Buy | Jefferies & Company Inc. | |
| 11.02.25 | Richemont Buy | UBS AG | |
| 11.02.25 | UBS Outperform | RBC Capital Markets | |
| 11.02.25 | ABB (Asea Brown Boveri) Neutral | Goldman Sachs Group Inc. | |
| 10.02.25 | Roche Sell | Goldman Sachs Group Inc. | |
| 10.02.25 | Roche Outperform | Bernstein Research | |
| 08.02.25 | ams-OSRAM Buy | Jefferies & Company Inc. | |
| 07.02.25 | UBS Halten | DZ BANK | |
| 07.02.25 | ABB (Asea Brown Boveri) Kaufen | DZ BANK | |
| 07.02.25 | UBS Overweight | JP Morgan Chase & Co. | |
| 06.02.25 | Nestlé Neutral | UBS AG | |
| 06.02.25 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 06.02.25 | Roche Sell | Goldman Sachs Group Inc. | |
| 06.02.25 | UBS Buy | Goldman Sachs Group Inc. | |
| 05.02.25 | Zurich Insurance Hold | Deutsche Bank AG | |
| 05.02.25 | Nestlé Market-Perform | Bernstein Research | |
| 04.02.25 | Roche Sell | Deutsche Bank AG | |
| 04.02.25 | UBS Buy | Goldman Sachs Group Inc. | |
| 04.02.25 | UBS Hold | Deutsche Bank AG | |
| 04.02.25 | UBS Overweight | JP Morgan Chase & Co. | |
| 04.02.25 | Novartis Buy | Deutsche Bank AG | |
| 04.02.25 | UBS Outperform | RBC Capital Markets | |
| 04.02.25 | UBS Buy | Goldman Sachs Group Inc. | |
| 03.02.25 | Roche Underweight | JP Morgan Chase & Co. | |
| 03.02.25 | Novartis Hold | Deutsche Bank AG | |
| 03.02.25 | Novartis Kaufen | DZ BANK | |
| 03.02.25 | Nestlé Neutral | UBS AG | |
| 03.02.25 | Novartis Buy | UBS AG | |
| 31.01.25 | Roche Sell | Deutsche Bank AG | |
| 31.01.25 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 31.01.25 | Novartis Buy | UBS AG | |
| 31.01.25 | ABB (Asea Brown Boveri) Sell | Deutsche Bank AG |